
    
      This Phase 2 safety, tolerability and efficacy study is designed as a double-blind,
      randomized, placebo-controlled study.

      This is a 7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of
      patients with RTT 18 years or older. A voluntary option will be offered for all patients who
      meet the exposure criteria for ANAVEX2-73 to continue a 12-week open label extension.
    
  